These systematic reviews led to current international guidelines for not recommending DOACs for secondary prevention of thrombotic APS, especially in the context of arterial thrombosis and triple positive aPL patients [42,43]. The gene discussed is FASLG; the disease is autoimmune polyendocrinopathy.